Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 11/20 | 0.55 |
| ▸ | INSR | P06213 | 2/20 | 0.55 |
| ▸ | IGF1R | P08069 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | ROS1 | P08922 | 1/20 | 0.55 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.55 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29173222 | 0.90 | EGFR (0.56) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL27076010 | 0.90 | EGFR (0.63) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL27076074 | 0.87 | EGFR (0.65) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL26379415 | 0.85 | EGFR (0.69) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL30936873 | 0.83 | EGFR (0.50) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL27076087 | 0.83 | EGFR (0.62) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL30014885 | 0.82 | EGFR (0.57) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL27076056 | 0.82 | EGFR (0.57) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL27076057 | 0.82 | EGFR (0.63) | EGFR | |
| SCHEMBL27076101 | 0.82 | EGFR (0.63) | EGFRALKINSRIGF1RMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297194-B2 | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | Bridge Biotherapeutics, Inc. (KR) | 2025-05-13 | — | — | US | disclosed |
| EP-4313969-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | Bridge Biotherapeutics, Inc. (KR) | 2024-02-07 | — | — | EP | disclosed |
| US-20220332711-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | Bridge Biotherapeutics, Inc. (KR) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297194-B2 | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | EGFR, ERBB2, ERBB4 | EGFR 1/4885ALK 90/4885INSR 1593/4885 |
| US-20220332711-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885ALK 90/4885INSR 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.